Loading
幸康 Stock: price and insider trades · Taiwan
TW·Mcap NT$3B
幸康: what insiders have been doing
This page follows insider dealings at 幸康 as filed with TWSE / TPEx (MOPS). In the past year (18 October 2025 to 18 October 2026), 6 filings came from 1 insider.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
No insider has bought 幸康 shares on the open market in the past twelve months. Publication is fast: at least half of the trades appear on TWSE / TPEx (MOPS) on the same day. That lag is the time during which only the insider knows about the trade.
These figures are compiled from regulatory filings published by TWSE / TPEx (MOPS). They describe what insiders did and are not a recommendation.
Insider Decl.
6
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Fundamental score
Ranked 5,086 of 24,148 companies
66.2
score / 100
Value63
Quality70
FCF yld5.8%
Earn yld5.7%
EV/EBITDA11.2x
ROE11%
Gross mgn36%
Net mgn11%
Debt/EBITDA0.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
NT$62
Analyst consensus
Income statement
RevenueNT$1.6B
Gross profitNT$581.9M36% margin
EBITDANT$269.8M17% margin
Net incomeNT$169.9M11.0% margin
Valuation
PER (trailing)15.8x
P/Book1.6x
Beta0.32
Balance sheet & cash
Market capNT$3B
Total debtNT$48.2M
Free Cash FlowNT$172.5M
Debt / Equity2%
Profitability & ownership
ROE10.7%
ROA4.0%
% insiders80.2%
% institutions0.0%
Last declaration on 27 April 2026
Declarations6 total
6 of 6 declarations
About 幸康
幸康 is a company listed on the XTAI market, specializing in the healthcare sector. It focuses on developing innovative solutions to enhance patient well-being.